Stay updated on Sustained Release Dalfampridine in Transverse Myelitis Clinical Trial

Sign up to get notified when there's something new on the Sustained Release Dalfampridine in Transverse Myelitis Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Sustained Release Dalfampridine in Transverse Myelitis Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    - Page template revision updated from v3.4.2 to v3.4.3. This is a metadata/update that does not affect study details or how users interact with the page.
    Difference
    0.1%
    Check dated 2026-03-11T18:12:46.000Z thumbnail image
  2. Check
    13 days ago
    No Change Detected
  3. Check
    20 days ago
    No Change Detected
  4. Check
    34 days ago
    Change Detected
    Summary
    Added Revision: v3.4.2. Removed the prior government funding status notice associated with v3.4.1.
    Difference
    0.4%
    Check dated 2026-02-11T06:32:02.000Z thumbnail image
  5. Check
    41 days ago
    Change Detected
    Summary
    A new system notice about government funding has been added. The site revision updated from v3.4.0 to v3.4.1.
    Difference
    0.5%
    Check dated 2026-02-04T05:23:14.000Z thumbnail image
  6. Check
    48 days ago
    Change Detected
    Summary
    Added a glossary toggle and updated metadata labels to show 'Last Update Submitted that Met QC Criteria', 'No FEAR Act Data', and a new footer 'Revision: v3.4.0', while the previous labels 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and version 'Revision: v3.3.4' were replaced.
    Difference
    0.2%
    Check dated 2026-01-28T02:58:46.000Z thumbnail image
  7. Check
    62 days ago
    Change Detected
    Summary
    Revision: v3.3.4 is now displayed, replacing Revision: v3.3.3. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-01-14T01:55:40.000Z thumbnail image
  8. Check
    84 days ago
    Change Detected
    Summary
    Footer revision updated to v3.3.3 and a separate 'Locations' section for Maryland was added, replacing the old 'Maryland Locations' label; the 'HHS Vulnerability Disclosure' link was removed. No study data or enrollment details were changed.
    Difference
    0.2%
    Check dated 2025-12-23T10:11:00.000Z thumbnail image

Stay in the know with updates to Sustained Release Dalfampridine in Transverse Myelitis Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Sustained Release Dalfampridine in Transverse Myelitis Clinical Trial page.